Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Identifieur interne : 001C57 ( Main/Corpus ); précédent : 001C56; suivant : 001C58Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Auteurs : Bruno Dubois ; David Burn ; Christopher Goetz ; Dag Aarsland ; Richard G. Brown ; Gerald A. Broe ; Dennis Dickson ; Charles Duyckaerts ; Jefferey Cummings ; Serge Gauthier ; Amos Korczyn ; Andrew Lees ; Richard Levy ; Irene Litvan ; Yoshikuni Mizuno ; Ian G. Mckeith ; C. Warren Olanow ; Werner Poewe ; Cristina Sampaio ; Eduardo Tolosa ; Murat EmreSource :
- Movement Disorders [ 0885-3185 ] ; 2007-12-15.
English descriptors
Abstract
A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21844
Links to Exploration step
ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher" sort="Goetz, Christopher" uniqKey="Goetz C" first="Christopher" last="Goetz">Christopher Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Medicine, University of Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, King's College, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broe, Gerald A" sort="Broe, Gerald A" uniqKey="Broe G" first="Gerald A." last="Broe">Gerald A. Broe</name><affiliation><mods:affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dickson, Dennis" sort="Dickson, Dennis" uniqKey="Dickson D" first="Dennis" last="Dickson">Dennis Dickson</name><affiliation><mods:affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name><affiliation><mods:affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cummings, Jefferey" sort="Cummings, Jefferey" uniqKey="Cummings J" first="Jefferey" last="Cummings">Jefferey Cummings</name><affiliation><mods:affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name><affiliation><mods:affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos" sort="Korczyn, Amos" uniqKey="Korczyn A" first="Amos" last="Korczyn">Amos Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Levy, Richard" sort="Levy, Richard" uniqKey="Levy R" first="Richard" last="Levy">Richard Levy</name><affiliation><mods:affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21844</idno><idno type="url">https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001C57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher" sort="Goetz, Christopher" uniqKey="Goetz C" first="Christopher" last="Goetz">Christopher Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Medicine, University of Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, King's College, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broe, Gerald A" sort="Broe, Gerald A" uniqKey="Broe G" first="Gerald A." last="Broe">Gerald A. Broe</name><affiliation><mods:affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dickson, Dennis" sort="Dickson, Dennis" uniqKey="Dickson D" first="Dennis" last="Dickson">Dennis Dickson</name><affiliation><mods:affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name><affiliation><mods:affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cummings, Jefferey" sort="Cummings, Jefferey" uniqKey="Cummings J" first="Jefferey" last="Cummings">Jefferey Cummings</name><affiliation><mods:affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name><affiliation><mods:affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos" sort="Korczyn, Amos" uniqKey="Korczyn A" first="Amos" last="Korczyn">Amos Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Levy, Richard" sort="Levy, Richard" uniqKey="Levy R" first="Richard" last="Levy">Richard Levy</name><affiliation><mods:affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15">2007-12-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2314">2314</biblScope><biblScope unit="page" to="2324">2324</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</idno><idno type="DOI">10.1002/mds.21844</idno><idno type="ArticleID">MDS21844</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PD dementia</term><term>Parkinson's disease</term><term>diagnostic criteria</term><term>executive functions</term><term>task force</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Bruno Dubois MD</name><affiliations><json:string>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</json:string></affiliations></json:item><json:item><name>David Burn MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University, United Kingdom</json:string></affiliations></json:item><json:item><name>Christopher Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Dag Aarsland MD, PhD</name><affiliations><json:string>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</json:string><json:string>School of Medicine, University of Bergen, Norway</json:string></affiliations></json:item><json:item><name>Richard G. Brown PhD</name><affiliations><json:string>Department of Psychology, King's College, London, United Kingdom</json:string><json:string>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Gerald A. Broe HB, BS</name><affiliations><json:string>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</json:string><json:string>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</json:string></affiliations></json:item><json:item><name>Dennis Dickson MD</name><affiliations><json:string>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</json:string></affiliations></json:item><json:item><name>Charles Duyckaerts MD, PhD</name><affiliations><json:string>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</json:string></affiliations></json:item><json:item><name>Jefferey Cummings MD</name><affiliations><json:string>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Serge Gauthier MD</name><affiliations><json:string>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Amos Korczyn MD, MSc</name><affiliations><json:string>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Andrew Lees FRCP</name><affiliations><json:string>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Richard Levy MD, PhD</name><affiliations><json:string>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</json:string></affiliations></json:item><json:item><name>Irene Litvan MD</name><affiliations><json:string>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Yoshikuni Mizuno MD</name><affiliations><json:string>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Ian G. McKeith MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</json:string></affiliations></json:item><json:item><name>C. Warren Olanow MD</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, USA</json:string><json:string>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</json:string></affiliations></json:item><json:item><name>Murat Emre MD</name><affiliations><json:string>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PD dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>diagnostic criteria</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>executive functions</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>task force</value></json:item></subject><articleId><json:string>MDS21844</json:string></articleId><language><json:string>eng</json:string></language><abstract>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>7.64</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1399</abstractCharCount><pdfWordCount>7054</pdfWordCount><pdfCharCount>45141</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>220</abstractWordCount></qualityIndicators><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><genre><json:string>review-article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>2324</last><first>2314</first></pages><issn><json:string>0885-3185</json:string></issn><issue>16</issue><subject><json:item><value>Viewpoint</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21844</json:string></doi><id>6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><author><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</p></note><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</affiliation></author><author><persName><forename type="first">David</forename><surname>Burn</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</affiliation></author><author><persName><forename type="first">Christopher</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Dag</forename><surname>Aarsland</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</affiliation><affiliation>School of Medicine, University of Bergen, Norway</affiliation></author><author><persName><forename type="first">Richard G.</forename><surname>Brown</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Psychology, King's College, London, United Kingdom</affiliation><affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</affiliation></author><author><persName><forename type="first">Gerald A.</forename><surname>Broe</surname></persName><roleName type="degree">HB, BS</roleName><affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</affiliation><affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</affiliation></author><author><persName><forename type="first">Dennis</forename><surname>Dickson</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</affiliation></author><author><persName><forename type="first">Charles</forename><surname>Duyckaerts</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</affiliation></author><author><persName><forename type="first">Jefferey</forename><surname>Cummings</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">Serge</forename><surname>Gauthier</surname></persName><roleName type="degree">MD</roleName><affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</affiliation></author><author><persName><forename type="first">Amos</forename><surname>Korczyn</surname></persName><roleName type="degree">MD, MSc</roleName><affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><roleName type="degree">FRCP</roleName><affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Richard</forename><surname>Levy</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</affiliation></author><author><persName><forename type="first">Irene</forename><surname>Litvan</surname></persName><roleName type="degree">MD</roleName><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</affiliation></author><author><persName><forename type="first">Yoshikuni</forename><surname>Mizuno</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</affiliation></author><author><persName><forename type="first">Ian G.</forename><surname>McKeith</surname></persName><roleName type="degree">MD</roleName><affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</affiliation></author><author><persName><forename type="first">C. Warren</forename><surname>Olanow</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</affiliation><affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</affiliation></author><author><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</affiliation></author><author><persName><forename type="first">Murat</forename><surname>Emre</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2314">2314</biblScope><biblScope unit="page" to="2324">2324</biblScope></imprint></monogr><idno type="istex">6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</idno><idno type="DOI">10.1002/mds.21844</idno><idno type="ArticleID">MDS21844</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>PD dementia</term></item><item><term>diagnostic criteria</term></item><item><term>executive functions</term></item><item><term>task force</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Viewpoint</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-02-12">Received</change><change when="2007-10-16">Registration</change><change when="2007-12-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="160"><doi origin="wiley" registered="yes">10.1002/mds.v22:16</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">16</numbering></numberingGroup><coverDate startDate="2007-12-15">15 December 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21844</doi><idGroup><id type="unit" value="MDS21844"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Viewpoint</title><title type="tocHeading1">Viewpoint</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-02-12"></event><event type="manuscriptRevised" date="2007-08-03"></event><event type="manuscriptAccepted" date="2007-10-16"></event><event type="firstOnline" date="2007-12-20"></event><event type="publishedOnlineFinalForm" date="2007-12-20"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2314</numbering><numbering type="pageLast">2324</numbering></numberingGroup><correspondenceTo>Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21844.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="70"></count><count type="wordTotal" number="7944"></count></countGroup><titleGroup><title type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><title type="short" xml:lang="en">Diagnostic Procedures for PD Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName><degrees>MD</degrees></personName><contactDetails><email>bruno.dubois@psl.aphp.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>David</givenNames><familyName>Burn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Christopher</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4 #af5"><personName><givenNames>Dag</givenNames><familyName>Aarsland</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af6 #af7"><personName><givenNames>Richard G.</givenNames><familyName>Brown</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af8 #af9"><personName><givenNames>Gerald A.</givenNames><familyName>Broe</familyName><degrees>HB, BS</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Dennis</givenNames><familyName>Dickson</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Charles</givenNames><familyName>Duyckaerts</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Jefferey</givenNames><familyName>Cummings</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Serge</givenNames><familyName>Gauthier</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Amos</givenNames><familyName>Korczyn</familyName><degrees>MD, MSc</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>FRCP</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af16"><personName><givenNames>Richard</givenNames><familyName>Levy</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af17"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af18"><personName><givenNames>Yoshikuni</givenNames><familyName>Mizuno</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af19"><personName><givenNames>Ian G.</givenNames><familyName>McKeith</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af20 #af21"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af22"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af23"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au20" creatorRole="author" affiliationRef="#af24"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au21" creatorRole="author" affiliationRef="#af25"><personName><givenNames>Murat</givenNames><familyName>Emre</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="NO" type="organization"><unparsedAffiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="NO" type="organization"><unparsedAffiliation>School of Medicine, University of Bergen, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="GB" type="organization"><unparsedAffiliation>Department of Psychology, King's College, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="GB" type="organization"><unparsedAffiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AU" type="organization"><unparsedAffiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="AU" type="organization"><unparsedAffiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="FR" type="organization"><unparsedAffiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="CA" type="organization"><unparsedAffiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="US" type="organization"><unparsedAffiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af18" countryCode="JP" type="organization"><unparsedAffiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af19" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af20" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af21" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af22" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af23" countryCode="PL" type="organization"><unparsedAffiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af24" countryCode="ES" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af25" countryCode="TR" type="organization"><unparsedAffiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">PD dementia</keyword><keyword xml:id="kwd3">diagnostic criteria</keyword><keyword xml:id="kwd4">executive functions</keyword><keyword xml:id="kwd5">task force</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Diagnostic Procedures for PD Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleInfo><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</affiliation><description>Correspondence: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Burn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dag</namePart><namePart type="family">Aarsland</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</affiliation><affiliation>School of Medicine, University of Bergen, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard G.</namePart><namePart type="family">Brown</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychology, King's College, London, United Kingdom</affiliation><affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gerald A.</namePart><namePart type="family">Broe</namePart><namePart type="termsOfAddress">HB, BS</namePart><affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</affiliation><affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dennis</namePart><namePart type="family">Dickson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Charles</namePart><namePart type="family">Duyckaerts</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jefferey</namePart><namePart type="family">Cummings</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Serge</namePart><namePart type="family">Gauthier</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amos</namePart><namePart type="family">Korczyn</namePart><namePart type="termsOfAddress">MD, MSc</namePart><affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">FRCP</namePart><affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Levy</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoshikuni</namePart><namePart type="family">Mizuno</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ian G.</namePart><namePart type="family">McKeith</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</affiliation><affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murat</namePart><namePart type="family">Emre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-12-15</dateIssued><dateCaptured encoding="w3cdtf">2007-02-12</dateCaptured><dateValid encoding="w3cdtf">2007-10-16</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">70</extent><extent unit="words">7944</extent></physicalDescription><abstract lang="en">A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>PD dementia</topic><topic>diagnostic criteria</topic><topic>executive functions</topic><topic>task force</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Viewpoint</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>16</number></detail><extent unit="pages"><start>2314</start><end>2324</end><total>11</total></extent></part></relatedItem><identifier type="istex">6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</identifier><identifier type="DOI">10.1002/mds.21844</identifier><identifier type="ArticleID">MDS21844</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001C57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2D
|texte= Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
}}
| This area was generated with Dilib version V0.6.23. |  |